The R&D heads of over 25 global biopharmaceutical companies have signed a joint letter expressing alarm over the impact of the Biden administration's new prescription medicine price negotiation power.
Global R&D heads sign joint letter expressing alarm over new pricing power
October 20, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Outcomes published from meeting the PBAC was directed to hold
June 22, 2025 - - Latest News -
TGA-licensed compounders call for review to ensure sustainability
June 20, 2025 - - Latest News -
GLP-1 pill study marks potential new chapter in treating diabetes and weight loss
June 20, 2025 - - Latest News -
An ideological darkness underpins our system's decision-making
June 20, 2025 - - Latest News -
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma